Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.01 - Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World

      00:00 - 00:00  |  Presenter: Yasushi Goto

      • Abstract

      Loading...

    • +

      P45.02 - Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Moushumi Suryavanshi

      • Abstract

      Loading...

    • +

      P45.03 - Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy

      00:00 - 00:00  |  Presenter: Enriqueta Felip

      • Abstract

      Loading...

    • +

      P45.04 - Phase II Study of Brigatinib in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Crizotinib: Barossa Cohort 2

      00:00 - 00:00  |  Presenter: Jun Sakakibara-Konishi

      • Abstract

      Loading...

    • +

      P45.05 - Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival

      00:00 - 00:00  |  Presenter: Sally CM Lau

      • Abstract

      Loading...

    • +

      P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

    • +

      P45.07 - Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC

      00:00 - 00:00  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

    • +

      P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

    • +

      P45.09 - Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada

      00:00 - 00:00  |  Presenter: Simren Chotai

      • Abstract

      Loading...

    • +

      P45.10 - Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis

      00:00 - 00:00  |  Presenter: Michela Febbraro

      • Abstract

      Loading...

    • +

      P45.11 - Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Oscar Arrieta

      • Abstract

      Loading...

    • +

      P45.12 - Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis

      00:00 - 00:00  |  Presenter: Chiara Paratore

      • Abstract

      Loading...

    • +

      P45.13 - Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort

      00:00 - 00:00

      • Abstract

      Loading...

    • +

      P45.14 - Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China

      00:00 - 00:00  |  Presenter: Shaoyu Yang

      • Abstract

      Loading...

    • +

      P45.15 - Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC

      00:00 - 00:00  |  Presenter: Zihua Zou

      • Abstract

      Loading...

    • +

      P45.16 - Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: David Riley

      • Abstract

      Loading...

    • +

      P45.17 - Outcomes of Patients on ALK Inhibitor Therapy in NHS Tayside Scotland UK

      00:00 - 00:00  |  Presenter: Sherie George

      • Abstract

      Loading...

    • +

      P45.18 - NSCLC Patients With ALK Gene Rearrangement – Croatian Experience

      00:00 - 00:00  |  Presenter: Marko Jakopović

      • Abstract

      Loading...